On April 27, Hualan Vaccine (301207) announced the first quarter report of 2025. The company's operating income was 24.28 million yuan, a year-on-year decrease of 29.0%; the net profit attributable to the parent company was 32.78 million yuan, a year-on-year decrease of 15.1%; the net profit attributable to the parent company after deducting non-recurring items was 15.42 million yuan, a year-on-year increase of 8.9%; the net cash flow from operations was -2.59 million yuan, a year-on-year decrease of 102.7%; EPS (fully diluted) was 0.0545 yuan.

As of the end of the first quarter, the company's total assets were 7.443 billion yuan, a decrease of 1.1% from the end of the previous year; the net assets attributable to the parent company were 6.048 billion yuan, an increase of 0.6% from the end of the previous year.

The company mainly focuses on the research and development, production and sales of biological vaccines, and is committed to providing high-quality vaccine products for public health. In addition, the company has also expanded related businesses in the field of biopharmaceuticals, involving the research and development and production of biological products, striving to occupy a larger market share in the biopharmaceutical industry.

The report shows that the company's overall operations in the first quarter faced certain challenges, with a decline in operating income and a year-on-year decrease in net profit attributable to shareholders of listed companies. At the same time, the company received certain government subsidies for non-recurring gains and losses, which provided certain support for the company's operations. Despite this, the net cash flow generated by operating activities was negative, indicating that the company needs to further strengthen its cash flow management.

https://finance.eastmoney.com/a/202504273390269248.html